Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) General Information

Description

A portfolio of cancer cell therapy assets based in England, United Kingdom.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • England, United Kingdom
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
US WorldMeds
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)‘s full profile, request access.

Request a free trial

Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)‘s full profile, request access.

Request a free trial

Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) FAQs

  • Where is Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) headquartered?

    Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) is headquartered in United Kingdom.

  • What industry is Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) in?

    Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)’s primary industry is Buildings and Property.

  • Is Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) a private or public company?

    Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) is a Private company.

  • What is the current valuation of Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)?

    The current valuation of Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) is .

  • What is Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)’s current revenue?

    The current revenue for Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) is .

  • Who are Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)’s investors?

    Adaptimmune Therapeutics has invested in Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets).

  • When was Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) acquired?

    Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) was acquired on 27-Jul-2025.

  • Who acquired Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets)?

    Adaptimmune Therapeutics (TECELRA, lete-cel, afami-cel and uza-cel Cell Therapy Assets) was acquired by US WorldMeds.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process